225
Participants
Start Date
November 11, 2020
Primary Completion Date
February 20, 2026
Study Completion Date
February 20, 2026
Forimtamig
Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
New Zealand Clinical Research - Auckland, Auckland
Rigshospitalet, København Ø
Peter MacCallum Cancer Center, Melbourne
Odense Universitetshospital, Odense C
UZ Gent, Ghent
Instituto Clinico Humanitas, Rozzano
Fond. IRCCS Istituto Nazionale Tumori, Milan
Clinica Universitaria de Navarra, Pamplona
Hopital De Haut Leveque, Pessac
Hospital Clinico Universitario de Salamanca, Salamanca
Hospital Universitario Marques de Valdecilla, Santander
Policlinico S.Orsola-Malpighi, Bologna
CHU NANTES - Hôtel Dieu, Nantes
CHRU Lille - Hôpital Claude Huriez, Lille
IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale Ematologia Oncologica, Napoli
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
Seoul St Mary's Hospital, Seoul
St James University Hospital, Leeds
University College London Hospitals NHS Foundation Trust, London
Hoffmann-La Roche
INDUSTRY